Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

3623 - Clinical practice evaluation of opioids induced constipation management in oncologic patients: The EIO-50 project.


22 Oct 2018


Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care


Supportive Care and Symptom Management

Tumour Site


Javier Salvador Bofill


Annals of Oncology (2018) 29 (suppl_8): viii603-viii640. 10.1093/annonc/mdy300


J. Salvador Bofill1, V. Guillem Porta2, M. Feyjoo3, A. Anton Torres4, E. Aranda Aguilar5, C. Camps6, A. Carrato Mena7, M. Constenla Figueiras8, J.J. Cruz Hernandez9, E. Diaz Rubio10, J. Garcia Foncillas11, P.N. Gascon12, R. Lopez Lopez13, B. Soler14, Y. Escobar15

Author affiliations

  • 1 Medical Oncology, Hospital Virgen del Rocio, 41014 - Sevilla/ES
  • 2 Medical Oncology, Fundación Instituto Valenciano de Oncología, 46009 - Valencia/ES
  • 3 Medical Oncology, Hospital Universitario La Moraleja, Sanitas, 28050 - Madrid/ES
  • 4 Medical Oncology, Hospital Miguel Servet, 50009 - Zaragoza/ES
  • 5 Medical Oncology, University Hospital Reina Sofia, 14004 - Cordoba/ES
  • 6 Medical Oncology, Consorcio Hospital General Universitario de Valencia, 46014 - Valencia/ES
  • 7 Medical Oncology, Hospital Universitario Ramon y Cajal, 28031 - Madrid/ES
  • 8 Medical Oncology, Complejo Hospitalario de Pontevedra, 36001 - Pontevedra/ES
  • 9 Medical Oncology, Hospital Universitario de Salamanca, 37007 - Salamanca/ES
  • 10 Vicepresidente, Real Academia de Medicina, IdISCC, CIBERONC, 28040 - Madrid/ES
  • 11 Medical Oncology, University Hospital "Fundacion Jimenez Diaz", 28040 - Madrid/ES
  • 12 Division Of Medical Oncology, Hospital Clinic y Provincial de Barcelona, 08036 - Barcelona/ES
  • 13 Medical Oncology, Complejo Hospitalario Universitario de Santiago de Compostela SERGAS, 15706 - Santiago de Compostela/ES
  • 14 Medical Department, E-C-BIO, S.L, 28232 - Madrid/ES
  • 15 Department Of Medical Oncology, Hospital General Universitario Gregorio Marañón, 28007 - Madrid/ES


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 3623


Opioid-induced constipation (OIC) is a common distressing symptom associated with cancer pain opioid treatment. Beyond the recommendations for the treatment of OIC, there are no specific guidelines for the management of the patient with OIC and little is known about the decision tree health care professional (HCP) use to manage OIC. The ECO Foundation (Excellence and Quality in Oncology) has promoted this study to learn about the diagnostic and treatment criteria of OIC in clinical practice.


An on-line survey was completed by 135 investigators: 122 medical oncologists (90.4%) and 13 palliative care specialists (9.6%). The questionnaire included 50 items about the management of OIC.


According to HCP, most of the cancer patients with pain (71.2%), received opioid treatment for more than 6 months and 54.4% developed OIC. Although 97% of HCP considered OIC as a major health problem only 14.8% of HCP used algorithms for the diagnosis of OIC and 14.1% for OIC treatment. Laxatives were considered second-line treatment for 60% of HCP, after healthy life-style recommendations. Laxatives were prescribed by 99.3% of HCP, but only 38.3% recommended them throughout the opioid treatment period. HCP considered laxatives did not achieve a therapeutic response on 33% of the cases. Peripherally Active µ-Opioid Receptor Antagonist (PAMORA) were considered by 80% of HCP a good alternative for the specific treatment of OIC in cancer patients. Indeed, PAMORA were considered the most effective measure with a score of 8 out of a 10 points scale.


OIC is considered a frequent and relevant opioid side effect among cancer patients in Spain. Although most HCP are aware of the potential for OIC with opioid treatment, there is limited consensus on the OIC diagnostic and treatment criteria. The insufficient efficacy of traditional therapies and the emerging of more specific and effective pharmacological approaches, suggest new clinical guidelines are needed for the management of OIC in cancer patients.

Clinical trial identification

Legal entity responsible for the study

ECO Foundation.


Kyowa Kirin Pharmaceutical.

Editorial Acknowledgement


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.